- Home
- PXLW vs IGC Comparison
PXLW vs IGC Comparison
Compare PXLW & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- IGC
- Stock Information
- Founded
- PXLW 1997
- IGC 2005
- Country
- PXLW United States
- IGC United States
- Employees
- PXLW N/A
- IGC N/A
- Industry
- PXLW Semiconductors
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- PXLW Technology
- IGC Health Care
- Exchange
- PXLW Nasdaq
- IGC Nasdaq
- Market Cap
- PXLW 42.0M
- IGC 39.8M
- IPO Year
- PXLW 2000
- IGC N/A
- Fundamental
- Price
- PXLW $6.13
- IGC $0.39
- Analyst Decision
- PXLW Strong Buy
- IGC Strong Buy
- Analyst Count
- PXLW 3
- IGC 2
- Target Price
- PXLW $13.67
- IGC $4.00
- AVG Volume (30 Days)
- PXLW 465.8K
- IGC 939.9K
- Earning Date
- PXLW 11-11-2025
- IGC 11-14-2025
- Dividend Yield
- PXLW N/A
- IGC N/A
- EPS Growth
- PXLW N/A
- IGC N/A
- EPS
- PXLW N/A
- IGC N/A
- Revenue
- PXLW $33,961,000.00
- IGC $1,327,000.00
- Revenue This Year
- PXLW N/A
- IGC $3.54
- Revenue Next Year
- PXLW $23.74
- IGC $15.12
- P/E Ratio
- PXLW N/A
- IGC N/A
- Revenue Growth
- PXLW N/A
- IGC 24.95
- 52 Week Low
- PXLW $4.67
- IGC $0.25
- 52 Week High
- PXLW $15.42
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- PXLW 36.39
- IGC 43.88
- Support Level
- PXLW $6.00
- IGC $0.38
- Resistance Level
- PXLW $6.47
- IGC $0.45
- Average True Range (ATR)
- PXLW 0.40
- IGC 0.02
- MACD
- PXLW -0.12
- IGC -0.00
- Stochastic Oscillator
- PXLW 9.68
- IGC 29.84
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.